Sanofi (NASDAQ:SNY) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. boosted its position in Sanofi (NASDAQ:SNY) by 1.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,707,057 shares of the company’s stock after purchasing an additional 29,536 shares during the period. American Century Companies Inc. owned approximately 0.07% of Sanofi worth $82,331,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SNY. Boston Partners raised its holdings in shares of Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after purchasing an additional 2,501,073 shares in the last quarter. Franklin Resources Inc. grew its position in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after buying an additional 395,744 shares during the last quarter. Magnetar Financial LLC increased its holdings in shares of Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after buying an additional 1,705,148 shares in the last quarter. Natixis Advisors LLC lifted its position in shares of Sanofi by 1.2% during the 4th quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company’s stock valued at $140,350,000 after acquiring an additional 35,828 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Sanofi during the 4th quarter worth $135,933,000. 14.04% of the stock is owned by institutional investors.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $55.93 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a one year low of $45.22 and a one year high of $60.12. The business’s 50-day moving average price is $54.70 and its two-hundred day moving average price is $52.84. The company has a market capitalization of $141.94 billion, a P/E ratio of 22.46, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on SNY. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, The Goldman Sachs Group started coverage on Sanofi in a research note on Friday. They issued a “neutral” rating and a $65.00 price objective for the company. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.